BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 22427472)

  • 1. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Ghasemzadeh M
    Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Jalali A; Ghasemzadeh M
    Leuk Res; 2013 May; 37(5):516-9. PubMed ID: 23395341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation.
    Danzer M; Polin H; Pröll J; Haunschmid R; Hofer K; Stabentheiner S; Hackl C; Kasparu H; König J; Hauser H; Binder M; Weiss R; Gabriel C; Krieger O
    Transplantation; 2009 Aug; 88(4):528-32. PubMed ID: 19696636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
    Kanga U; Mourya M; Seth T; George J; Sood P; Sharma R; Saxena A; Mehra NK
    Transplant Proc; 2012 May; 44(4):919-21. PubMed ID: 22564585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation.
    Tamouza R; Busson M; Rocha V; Fortier C; Haddad Y; Brun M; Boukouaci W; Bleux H; Socié G; Krishnamoorthy R; Toubert A; Gluckman E; Charron D
    Transplantation; 2006 Dec; 82(11):1436-40. PubMed ID: 17164714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell transplantation in Egyptian patients.
    Mossallam GI; Fattah RA; El-Haddad A; Mahmoud HK
    Hum Immunol; 2015 Mar; 76(2-3):161-5. PubMed ID: 25543014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
    Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.
    Sobecks RM; Askar M; Thomas D; Rybicki L; Kalaycio M; Dean R; Avery R; Mossad S; Copelan E; Bolwell BJ
    Exp Clin Transplant; 2011 Feb; 9(1):7-13. PubMed ID: 21605017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation.
    Park Y; Cheong JW; Park MH; Kim MS; Kim JS; Kim HS
    Hum Immunol; 2016 Feb; 77(2):176-83. PubMed ID: 26602146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
    Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY
    Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation.
    Russell CA; Heilmann C; Madsen HO; Vindeløv LL
    Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.
    Ludajic K; Balavarca Y; Bickeböller H; Rosenmayr A; Fae I; Fischer GF; Kouba M; Pohlreich D; Kalhs P; Greinix HT
    Bone Marrow Transplant; 2009 Jul; 44(2):97-103. PubMed ID: 19169284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
    Murphy N; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King B; Macgregor L; Holdsworth R; McCluskey J; Tait BD
    Bone Marrow Transplant; 2006 Apr; 37(8):773-9. PubMed ID: 16518429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
    Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
    Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.